Literature DB >> 19225419

Healthcare for obstructive lung disease in an industrial spirometry surveillance program.

Mridu Gulati1, Martin D Slade, Martha G Fiellin, Mark R Cullen.   

Abstract

OBJECTIVE: The efficacy of workplace spirometry surveillance programs is unclear. We examine whether aluminum industry workers with airflow obstruction (AO) received health care for obstructive lung disease.
METHODS: We performed a cross sectional analysis over 7 years of 6821 aluminum production workers. The primary outcome was the association between obstructive lung disease insurance claims and the presence of AO. We also examined whether the presence of claims was associated with increasing AO severity.
RESULTS: Although workers with AO more frequently had claims, 60% of workers with AO, most frequently those with mild and borderline obstruction, had no claim.
CONCLUSIONS: Workers with AO, particularly borderline and mild obstruction, frequently do not receive health care despite respiratory surveillance. Further investigation is needed to determine if workers with undiagnosed AO are symptomatic or have accelerated losses in lung function over time.

Entities:  

Mesh:

Year:  2009        PMID: 19225419      PMCID: PMC3711683          DOI: 10.1097/JOM.0b013e3181954ae6

Source DB:  PubMed          Journal:  J Occup Environ Med        ISSN: 1076-2752            Impact factor:   2.162


  28 in total

1.  Clinical and occupational outcomes in health care workers with natural rubber latex allergy.

Authors:  David I Bernstein; Ravi Karnani; Ray E Biagini; Cheryl K Bernstein; Karen Murphy; Brian Berendts; Jonathan A Bernstein; Leonard Bernstein
Journal:  Ann Allergy Asthma Immunol       Date:  2003-02       Impact factor: 6.347

2.  Association between chronic obstructive pulmonary disease and employment by industry and occupation in the US population: a study of data from the Third National Health and Nutrition Examination Survey.

Authors:  Eva Hnizdo; Patricia A Sullivan; Ki Moon Bang; Gregory Wagner
Journal:  Am J Epidemiol       Date:  2002-10-15       Impact factor: 4.897

3.  Respiratory symptoms and lung-function changes with exposure to five substances in aluminium smelters.

Authors:  Lin Fritschi; Malcolm R Sim; Andrew Forbes; Michael J Abramson; Geza Benke; A William Musk; Nicholas H de Klerk
Journal:  Int Arch Occup Environ Health       Date:  2003-01-18       Impact factor: 3.015

Review 4.  Does aluminum smelting cause lung disease?

Authors:  M J Abramson; J H Wlodarczyk; N A Saunders; M J Hensley
Journal:  Am Rev Respir Dis       Date:  1989-04

5.  Potroom asthma: New Zealand experience and follow-up.

Authors:  T V O'Donnell; B Welford; E D Coleman
Journal:  Am J Ind Med       Date:  1989       Impact factor: 2.214

6.  Pulmonary function testing in the screening of workers: guidelines for instrumentation, performance, and interpretation.

Authors:  J L Hankinson
Journal:  J Occup Med       Date:  1986-10

7.  Health survey of aluminum workers with special reference to fluoride exposure.

Authors:  N L Kaltreider; M J Elder; L V Cralley; M O Colwell
Journal:  J Occup Med       Date:  1972-07

8.  Changes in rates and severity of compensation claims for asthma due to diisocyanates: a possible effect of medical surveillance measures.

Authors:  S M Tarlo; G M Liss; K S Yeung
Journal:  Occup Environ Med       Date:  2002-01       Impact factor: 4.402

Review 9.  The size of the problem of managing asthma.

Authors:  Peter J Barnes
Journal:  Respir Med       Date:  2004-10       Impact factor: 3.415

Review 10.  Control of occupational asthma and allergy in the detergent industry.

Authors:  Katherine Sarlo
Journal:  Ann Allergy Asthma Immunol       Date:  2003-05       Impact factor: 6.347

View more
  1 in total

1.  Contribution of health status and prevalent chronic disease to individual risk for workplace injury in the manufacturing environment.

Authors:  Jessica Kubo; Benjamin A Goldstein; Linda F Cantley; Baylah Tessier-Sherman; Deron Galusha; Martin D Slade; Isabella M Chu; Mark R Cullen
Journal:  Occup Environ Med       Date:  2013-10-16       Impact factor: 4.402

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.